Myostatin in combination with creatine phosphokinase or albumin may differentiate patients with cirrhosis and sarcopenia

Authors:

Abstract
Background/Objectives:In patients with liver cirrhosis (LC), sarcopenia is correlated with frequent complications and increased mortality. Myostatin-a myokine-is a potential biomarker of skeletal mass and/or sarcopenia. The aim of this study was to examine the association between myostatin and muscle-mass and evaluate myostatin as a biomarker of sarcopenia in LC. Methods: Skeletal-muscle-index (SMI) and myosteatosis were evaluated by computed tomography scan. Muscle quantity and quality along with muscle strength and function were used to diagnose sarcopenia. Serum myostatin was measured by ELISA. Results:115 consecutive patients with LC [72.2% male, median age 59-years (IQR 52-67), MELD 12 (8-16), 28.7% with compensated LC] were included. Low SMI was diagnosed in 49.6% and sarcopenia in 34.8% (21.7% severe). Myostatin levels were lower in low (p10myostatin-to-CPK or albumin-to-myostatin were found to have acceptable diagnostic accuracy in ruling out sarcopenia in total patients. However, the best diagnostic performance was shown in MELD≥15 (AUROC 0.829 or 0.801, respectively). Conclusions:Myostatin is independently associated with both skeletal muscle mass and sarcopenia. Myostatin in combination with CPK or albumin are good surrogate markers in excluding sarcopenia.

This publication has 45 references indexed in Scilit: